Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter Phase Ib Study of The Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors

Next Previous
X
Search
Trial Profile

An Open-Label, Multicenter Phase Ib Study of The Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Capecitabine; Cisplatin; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel; Vanucizumab
  • Indications Adenocarcinoma; Gastric cancer; Liver cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Chugai Pharmaceutical; Roche

    • Most Recent Events

    • 01 Dec 2022 Results assessing Molecular correlation of clinical response and resistance to atezolizumab in combination with bevacizumab in tumor by collecting samples from patients with hepatocellular carcinoma enrolled in the GO30140 phase 1b or IMbrave150, published in the Nature Medicine
    • 01 Aug 2022 Results assessing Molecular correlation of clinical response and resistance to atezolizumab in combination with bevacizumab in tumor by collecting samples from patients with hepatocellular carcinoma enrolled in the GO30140 phase 1b or IMbrave150, published in the Nature Medicine
    • 18 Apr 2022 Data was used from trials (GO30140 and IMbrave150) to assess Alpha-fetoprotein as a potential surrogate biomarker for atezolizumab + bevacizumab treatment of hepatocellular carcinoma published in the Clinical Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top